Keyword: Novartis Venture Fund
The CHF 35 million series A round sets Anaveon up to advance a preclinical asset designed to enhance anti-tumor immune responses.
Ribon Therapeutics has come out with a series B with focused on monoPARPs against cancer, inflammatory disorders and neurodegenerative diseases.
28-7 Therapeutics launched with $65 million to fund its cancer treatments that aim to increase the levels of tumor-suppressing RNA genes.
The financing tees up Enterprise to take three projects into the clinic and push one of them through a midphase proof-of-concept trial.
UCSF scientist Shaun Coughlin will lead CV research at NIBR, Novo's China GM was promoted to EVP, and Cavion poached Teva exec to head up R&D.
Cavion has seen Spyridon "Spyros" Papapetropoulos join its ranks as EVP of research and development and CMO.
NeuroVia gets $14 million to treat rare CNS disorder X-linked adrenoleukodystrophy.
Bicycle Therapeutics has returned to its big name backers for £40 million to fund the advance of cancer candidates into the clinic.
Newly born European biotech Vivet Therapeutics has started life with €37.5 million ($41 million) and an executive team made up of Novartis, Sanofi and Gensight veterans, as the company looks to get to work on its gene therapies for a host of rare diseases.